Mucositis News and Research

RSS

Fearing the deadly combo of COVID-19 and cancer

Three Tuesdays each month, Katherine O'Brien straps on her face mask and journeys about half an hour by Metra rail to Northwestern University's Lurie Cancer Center.

25 Jun 2020

Study: Vitamin D can reduce side effects associated with chemotherapy

As many cancer patients will confirm, the chemotherapy prescribed to kill the disease is often more debilitating than the cancer itself, with a range of horrendous side effects.

18 Jun 2020

Antioxidant-rich foods can lower risk of infection in children with leukemia

While encouraging children to eat their fruits and veggies is a common refrain for most parents, new research led by a pediatric oncology expert from Roswell Park Comprehensive Cancer Center underscores that diets high in antioxidant-rich foods can have particular benefits for young cancer patients.

2 May 2020

Braincool completes patient recruitment to study Cooral System for prevention of Oral Mucositis

BrainCool AB, a Swedish medical device innovator, and a world leader in medical cooling technology for therapeutic hypothermia (brain cooling) and oncology, is pleased to announce that it has completed patient recruitment in the Scandinavian multi-center pivotal trial of 180 patients to investigate the patented Cooral® System for prevention of Oral Mucositis, one of the most debilitating side-effects of both standard and high-dose chemotherapeutic oncology treatments.

11 Feb 2020

ATS publishes clinical guideline on laboratory diagnosis of fungal infections

The American Thoracic Society has published an official clinical guideline on laboratory diagnosis of fungal infections in pulmonary and critical care medicine in the Society's Aug. 30 American Journal of Respiratory and Critical Care Medicine.

30 Aug 2019

Magic mouthwash effectively reduces mouth sore pain caused by radiation therapy

"Magic mouthwash," an oral rinse containing diphenhydramine, lidocaine and antacids, significantly reduced pain from oral mucositis, mouth sores, in patients receiving radiation therapy for cancers of the head and neck when compared to plaecbo.

16 Apr 2019

Researchers to investigate light therapy as relief from painful side effect of cancer treatment

University at Buffalo researchers have received part of a $1.5 million grant to investigate light therapy as a replacement for prescription opioids in treating oral mucositis, painful ulcers and swelling in the mouth that result from chemotherapy and radiation treatment for cancer.

12 Feb 2019

FDA approves new treatment for AML patients

The U.S. Food and Drug Administration today approved Daurismo (glasdegib) tablets to be used in combination with low-dose cytarabine (LDAC), a type of chemotherapy, for the treatment of newly-diagnosed acute myeloid leukemia (AML) in adults who are 75 years of age or older or who have other chronic health conditions or diseases (comorbidities) that may preclude the use of intensive chemotherapy.

22 Nov 2018

NCCN adds COPIKTRA capsules to NCCN Guidelines for follicular lymphoma

Verastem, Inc., focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients, today announced that the National Comprehensive Cancer Network added COPIKTRA (duvelisib) capsules to the Clinical Practice Guidelines in Oncology (NCCN Guidelines) for follicular lymphoma.

8 Oct 2018

New drug shows potential to prevent painful side effect of therapy

About 50,000 people in the U.S. are diagnosed annually with head, neck, nasal and oral cancers. Most are treated with radiation, and of those, 70-80 percent develop a painful and debilitating side effect called severe oral mucositis.

20 Aug 2018

Clinical study suggests new treatment direction for head and neck cancer in heavy smokers

Patients with a greater than 10 pack/year history of smoking tend to develop an especially dangerous form of head and neck squamous cell cancer for which prognosis remains poor and treatments have changed little during the past two decades.

14 Aug 2018

New medication may treat chemotherapy, radiotherapy-induced oral mucositis

Researchers from the University of Granada have developed new medication which could help to treat and prevent chemotherapy and radiotherapy-induced oral mucositis in head and neck cancer patients.

30 Jun 2018

European regulatory approves BMG Pharma’s GelX for prevention of oral mucositis

BMG Pharma S.r.l., an innovative specialty pharmaceutical company, is pleased to announce the European regulatory approval for its GelX product to be used for the prevention of oral mucositis.

14 May 2018

Trial shows safety, feasibility of adding immunotherapy during chemoradiation for head and neck cancer

Analysis of a clinical trial, RTOG Foundation 3504, finds that nivolumab immunotherapy can be administered safely in conjunction with radiation therapy and chemotherapy for patients with newly diagnosed local-regionally advanced head and neck cancers.

13 Feb 2018

FDA approves first adjuvant treatment to reduce risk of kidney cancer recurrence

The U.S. Food and Drug Administration today approved Sutent (sunitinib malate) for the adjuvant treatment of adult patients who are at a high risk of kidney cancer (renal cell carcinoma) returning after a kidney has been removed (nephrectomy).

17 Nov 2017

Proton beam therapy has lower rates of toxicity in pediatric patients with head and neck cancer

Pediatric patients with head and neck cancer can be treated with proton beam therapy (PBT) instead of traditional photon radiation, and it will result in similar outcomes with less impact on quality of life.

23 Oct 2017

Pfizer receives FDA approval for new therapy to treat adults and children with AML

Pfizer Inc. today announced that the U.S. Food and Drug Administration approved MYLOTARG (gemtuzumab ozogamicin) for adults with newly diagnosed CD33-positive acute myeloid leukemia (AML), and adults and children 2 years and older with relapsed or refractory CD33-positive AML.

1 Sep 2017

FDA approves new drug and chemotherapy combination for treatment of adult patients with AML

The U.S. Food and Drug Administration today approved Rydapt (midostaurin) for the treatment of adult patients with newly diagnosed acute myeloid leukemia who have a specific genetic mutation called FLT3, in combination with chemotherapy.

28 Apr 2017

Stivarga receives expanded FDA approval for treatment of liver cancer

The U.S. Food and Drug Administration today expanded the approved use of Stivarga (regorafinib) to include treatment of patients with hepatocellular carcinoma (HCC or liver cancer) who have been previously treated with the drug sorafenib.